Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics strengthens its board

Professor Paul Workman joins as an independent director

Paul WorkmanDrug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board.

He said: “I am delighted to be joining the board of Storm and working with the company in this exploding area of biology.

“RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies.

“I look forward to working with the board to help guide Storm’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.”

Workman currently serves The Institute of Cancer Research as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research UK.

Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent director to Storm’s board.

“Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed.

“We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”

14th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics